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Background: Neuregulin-1 (NRG-1) has been shown to act as a neuroprotectant in animal models of nerve agent
intoxication and other acute brain injuries. We recently demonstrated that NRG-1 blocked delayed neuronal death in
rats intoxicated with the organophosphate (OP) neurotoxin diisopropylflurophosphate (DFP). It has been proposed that
inflammatory mediators are involved in the pathogenesis of OP neurotoxin-mediated brain damage.
Methods: We examined the influence of NRG-1 on inflammatory responses in the rat brain following DFP intoxication.
Microglial activation was determined by immunohistchemistry using anti-CD11b and anti-ED1 antibodies. Gene expression
profiling was performed with brain tissues using Affymetrix gene arrays and analyzed using the Ingenuity Pathway Analysis
software. Cytokine mRNA levels following DFP and NRG-1 treatment was validated by real-time reverse transcription
polymerase chain reaction (RT-PCR).
Results: DFP administration resulted in microglial activation in multiple brain regions, and this response was
suppressed by treatment with NRG-1. Using microarray gene expression profiling, we observed that DFP increased
mRNA levels of approximately 1,300 genes in the hippocampus 24 h after administration. NRG-1 treatment suppressed
by 50% or more a small fraction of DFP-induced genes, which were primarily associated with inflammatory responses.
Real-time RT-PCR confirmed that the mRNAs for pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-6
(IL-6) were significantly increased following DFP exposure and that NRG-1 significantly attenuated this transcriptional
response. In contrast, tumor necrosis factor α (TNFα) transcript levels were unchanged in both DFP and DFP + NRG-1
treated brains relative to controls.
Conclusion: Neuroprotection by NRG-1 against OP neurotoxicity is associated with the suppression of pro-
inflammatory responses in brain microglia. These findings provide new insight regarding the molecular mechanisms
involved in the neuroprotective role of NRG-1 in acute brain injuries.
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Organophosphorus (OP) nerve agents are rapidly acting and
toxic chemicals that have been used by terrorists in military
combat and against civilian populations [1,2]. A recent
United Nations report confirmed that Syria used sarin gas in
an attack against a civilian population [3], killing 1,400
people, including more than 400 children in the suburbs of
Damascus. OP nerve agents were also used in Iraq against
Kurdish civilians during the Iran-Iraq Gulf War of 1981 to
1987 [4]. In 1995, a Japanese doomsday cult used the nerve
agent sarin to kill seven people and poison 600 others in an
attack in the Japanese city of Matsumoto [5]. A year later,
the cult used sarin in a terrorist attack on the Tokyo subway
system that killed twelve and sent more than 5,000 people
to hospitals [6-8]. As threats of terrorism increase, the devel-
opment of therapeutic strategies for protecting the brain
against the neurotoxic effects of OP nerve agents has be-
come an important area of research.
OP nerve agents affect cholinergic neurotransmission
by inhibiting the enzyme acetylcholinesterase (AChE).
Current post-exposure medical countermeasures against
nerve agents (for example, atropine, oximes, and benzodi-
azepines) are useful in preventing mortality but are not
sufficiently effective in protecting the CNS from seizures
and permanent injury [1]. We recently demonstrated the
potential therapeutic benefit of neuregulin-1 (NRG-1)
in a rat model of acute OP poisoning [9]. NRG-1 be-
longs to a family of multipotent neuroprotective and
anti-inflammatory growth factors that include acetyl-
choline receptor inducing activities (ARIAs), glial
growth factors (GGFs), heregulins, and neu differenti-
ation factors (NDFs) [10-14]. Our studies showed that
NRG-1 reduced delayed neuronal death by approxi-
mately 90% in multiple brain regions of rats acutely
intoxicated with the OP diisopropylfluorophosphate
(DFP) when administered up to 1 h following DFP in-
toxication [9].
There is strong evidence that inflammatory reactions
are involved in OP-mediated neuronal injury and result
in poor prognosis of neurological outcome [2,15-19].
Brain microglial cells are rapidly activated in response to
OP nerve agents [20,21], and inflammatory cytokines, such
as interleukin-1 (interleukin-1α (IL-1α) and interleukin-
1β (IL-1β)), interleukin-6 (IL-6), and tumor necrosis fac-
tor α (TNFα) are induced in microglia and other cells in
the rodent brain following OP intoxication [22-27].
Therefore, in this study, we examined whether NRG-1
prevents OP-induced pro-inflammatory responses in
the brain. Our findings indicate that NRG-1 suppressed
DFP-induced microglial activation and brain levels of
mRNA encoding the pro-inflammatory cytokines IL-1β
and IL-6. These results may yield insight into the mech-
anisms involved in the neuroprotective efficacy of NRG-
1 in nerve-agent-induced brain injury.Methods
Animals and DFP exposures
All animals used in these studies were treated humanely
and with regard to alleviation of suffering and pain, and
all protocols involving animals were approved by the In-
stitutional Animal Care and Use Committee (IACUC) of
Morehouse School of Medicine, Oregon Health &
Science University and University of California, Davis
(UCD) prior to the initiation of experimentation. Adult
male Sprague–Dawley rats (280 to 320 g; Harlan
Laboratories, USA) were housed in standard plastic
cages in a temperature-controlled room (22°C ± 2°C) on
a 12-h reverse light–dark cycle. Food and water were
provided ad libitum. Animals were anesthetized with 2%
isoflurane (30% oxygen, 70% nitrous oxide) and injected
i.m. with pyridostigmine bromide (PB; P1339, TCI
America, Portland, OR) at 0.1 mg/kg body weight (BW)
in saline and with atropine methylnitrate (AMN; A0755,
TCI America) at 20 mg/kg BW in saline 30 and 10 min
prior to DFP injection, respectively. AMN and PB do
not readily cross the blood brain barrier, so these drugs
are centrally inactive [28] but effectively block peripheral
OP neurotoxicity, thereby reducing mortality and facili-
tating detection of seizure symptoms [29,30]. Animals
were then injected i.p. with DFP (D0879, Sigma Chem-
ical Co., St. Louis, MO) at 9 mg/kg BW diluted in sterile
distilled water as previously described [9,30]. DFP was
always prepared fresh within 5 min before administra-
tion. The intensity of seizures in the delayed neuronal
injury model was evaluated using a 5-point ranking sys-
tem specifically designed to measure seizure activity in
animals pre-treated with peripheral antidotes [29,31]. In
paradigm, seizure activity is noted only during the first
hour post-DFP exposure, and we observed that animals
that do not have tonic-clonic seizures during that hour
also do not exhibit injured neurons [30]. The animals
were observed for a period of 1 h after drug administra-
tions and animals not showing seizure activity were ex-
cluded. AChE activity was determined as previously
described [30].
Intra-arterial administration of NRG-1
The left common carotid artery (CCA) was exposed in
anesthetized animals through a midline incision and was
carefully dissected free from surrounding nerves and
fascia [32]. The occipital artery and superior thyroid
branches of the external carotid artery (ECA) were
isolated and electrocoagulated. The ECA was dissected
further distally. The internal carotid artery (ICA) was
isolated and carefully separated from the adjacent vagus
nerve, and the pterygopalatine artery was ligated close to
its origin with a 6–0 silk suture. Animals were random-
ized, and NRG-1 or vehicle was administered via the
ECA as a 10-μl single bolus of NRG-1β EGF-like domain
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phosphocitrate buffer, pH 5.0 with 1% BSA) using a
Hamilton syringe. The dose of NRG-1 was selected based
on previous studies of the neuroprotective efficacy of NRG-
1 against DFP neurotoxicity [9]. All surgical procedures were
performed using sterile/aseptic techniques in accordance
with IACUC guidelines. Animals were selected and random-
ized before DFP intoxication and treated with either NRG-1
(n= 7) or vehicle (phosphocitrate buffer, pH 5.0 with 1%
BSA; n= 7). NRG-1 and vehicle were administered inter-
arterially 5 min prior to DFP injection. In all studies,
anesthesia was stopped immediately following injection of
DFP. Rectal temperature was maintained between 36.5°C
and 37.0°C during anesthesia with a Homeothermic Blanket
Control Unit (Harvard Apparatus, Holliston, MA).
Histology and immunohistochemistry
At 24 h post-DFP injection, rats were deeply anesthetized
with 5% isoflurane and perfused transcardially with saline
followed by cold 4% PFA solution in PBS for 30 min.
Brains were quickly removed and cryoprotected in 30%
sucrose. Coronal sections of 20 μm thickness were cryo-
sectioned from the entire brain of each animal. Sections
were mounted on slides which were stored at −80°C until
further processed. Fluro-Jade B (FJB, AG310, Millipore,
Billerica, MA) labeling was performed as previously de-
scribed [30]. For immunostaining, after rinsing in 0.01 M
PBS, sections were blocked with PBS containing 5% nor-
mal goat serum and 0.1% triton X-100 for 1 h at 4°C.
Sections were then incubated for 1 h at 37°C with mouse
monoclonal anti-ED1 (1:500, MAB1435, Millipore) and
anti-CD11b (1:500, CBL1512, Millipore) antibodies. Sections
were washed with PBS and incubated with a Cy3-
conjugated goat anti-mouse IgG antibody (1:400, 115-165-
166, Jackson Laboratories, Bar Harbor, ME) for 1 h at room
temperature. All negative controls were incubated with PBS
instead of the primary antibodies. For dual labeling studies,
sections were first processed for immunohistochemistry as
described above, and then processed using a modified
method for FJB labeling. The modified protocol included
brief immersion in 0.015% KMnO4 for 1 min followed by
incubation in a 0.0001% solution of FJB solution for 8 min.
These modifications reduced the loss of immunohisto-
chemical staining and minimized fluorescent bleed-
through of FJB labeling during microscopy. The sections
were rinsed with distilled water and cover slipped with
mounting medium containing 0.1% acetic acid and 80%
glycerin. Fluorescence was visualized via indirect fluor-
escence microscopy.
RNA isolation and real-time reverse transcription
polymerase chain reaction
Total RNA was isolated from the hippocampus, cortex, and
the entire subcortex of each brain using TRIzol reagent(Life Technologies, Grand Island, NY; n = 7 to 9, per condi-
tion). RNA was treated with DNase I to remove any traces
of genomic DNA. First-strand cDNA was synthesized from
1 μg of each RNA sample using oligo (dT) and Omniscript
reverse transcriptase (Qiagen, Valencia, CA, USA) accord-
ing to the manufacturer’s protocol. Each set of samples was
simultaneously processed for RNA extraction, DNase I
treatment, cDNA synthesis, and PCR reaction. Real-time
reverse transcription polymerase chain reaction (RT-PCR)
was performed with SYBR Green (IQTM Sybr Green
Supermix, BioRad, Hercules, CA, USA) using an iCycler
(BioRad, Hercules, CA, USA). To quantify mRNA expres-
sion, primers for rat IL-1β (sense, 5′-aggcttccttgtgcaagtgt-
3′; antisense, 5′-tgagtgacactgccttcctg-3′), IL-6 (5′-ccgga-
gaggagacttcacag-3′; antisense, 5′-cagaattgccattgcacaac-3′),
TNFα (sense, 5′-agatgtggaactggcagagg-3′, antisense, 5′-
cccatttgggaacttctcct-3′), and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH; sense, 5′-acccagaagactgtggatgg-
3′; antisense, 5′-cacattgggggtaggaacac-3′) were used. Cyc-
ling parameters were 95°C 3.5 min, then 40 cycles of 95°C
for 10 s, 55°C for 45 s, 95°C 1 min, 55°C 1 min, and then
melt following the manufacturer’s protocol. The fluores-
cence of the accumulating product was measured at the
product melting temperature. To confirm the specificity of
PCR products, melting curves were determined using
iCycler software. mRNA levels were normalized against
GAPDH mRNA levels in the same sample. GAPDH mRNA
levels did not show any significant treatment-related vari-
ation in our experiment. PCR results are from naive animals
and control (PB +AMN+water), DFP (PB +AMN+DFP+
vehicle), and DFP +NRG-1 (PB +AMN+DFP +NRG-1)-
treated animals. Intensity values are means ± SEM. Statistical
analysis was carried out using ANOVA. Differences were
considered significant at the level of P < 0.05.
RNA preparation and GeneChip microarray analysis
Microarray analysis was performed using Affymetrix Gene-
Chips (Affymetrix, Santa Clara, CA, USA). Animals were
sacrificed 24 h after DFP and NRG-1 administration, and
hippocampal tissues from control, DFP treated, DFP +
NRG-1 treated animals (n = 3 per condition) were used for
subsequent RNA isolation. Total RNA was extracted with
TRIzol Reagent (Life Technologies, Grand Island, NY,
USA) followed by a further cleanup with the Ambion RNA-
queous kit (RNAqueous Kit, Ambion/Life Technologies,
Grand Island, NY). An Agilent bioanaylzer was used to
measure RNA integrity and the NanoDrop to measure
RNA quantity. cRNA was synthesized using a GeneChip 3′
IVT Express Kit according to the manufacturer’s protocol
(Affymetrix, Santa Clara, CA, USA). One hundred nano-
grams of RNA was used for the microarrays. Total RNA
was reversed transcribed to synthesize first-strand cDNA
and then converted into a double-stranded DNA. Amplified
RNA (aRNA) was synthesized by in vitro transcription and
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the molecule. The aRNA was then purified and fragmented
for hybridization onto GeneChip 3′ expression arrays.
Biotinylated aRNA was hybridized to an Affymetrix Rat
Genome U230 2.0 GeneChip with approximately 30,000
transcripts. The chips were hybridized at 45°C for 16 h, and
then washed, stained with streptavidin-phycoerythrin, and
scanned according to manufacturing guidelines.
Affymetrix microarray data analysis
We used this dataset to further examine the transcrip-
tional regulation of genes induced by DFP and suppressed
by NRG-1. Initial data analysis was performed using Affy-
metrix Expression Console software (Affymetrix, Santa
Clara, CA, USA). Affymetrix microarrays contain the
hybridization, labeling, and housekeeping controls to
evaluate the success of the hybridizations. Affymetrix
Transcriptome Analysis Console (TAC) Software per-
formed statistical analysis to enable the identification of
differentially expressed genes. Gene expression values thatFigure 1 Neuregulin-1 inhibits DFP-induced changes in microglial morpho
with PB (0.1 mg/kg, i.m.) and AMN (20 mg/kg, i.m.) 30 and 10 min, respectively, p
via injection into the carotid artery 5 min prior to DFP exposure. Control animals
used to identify resting and activated microglia in superficial layers of cortex (A, C
administration. CD11b immunopositive cells (red labeling) in the cortex (A) and t
morphology of resting microglia. In contrast, CD11b immunopositive cells in thes
characteristic of activated microglia (indicated by arrows), for example, increased
ramification of distal branches (C, E, G). CD11b immunopositive cells in DFP into
more closely resembled those observed in controls. Dual labeling with CD11b an
present in areas with significant neurodegeneration following DFP (G), but neithe
DFP intoxicated animals pretreated with NRG-1 (H). Scale bar = 50 μm.increased by twofold or more in TAC were determined
statistically significant (P < 0.005) using one-way ANOVA
and a threshold of the false discovery rate (FDR) based on
the Benjamini-Hochberg step-up FDR-controlling proced-
ure. Three chips were used for each experimental group:
control, DFP, and DFP +NRG-1. Genes in the hippocam-
pus of DFP intoxicated animals that increased in expres-
sion by twofold or more compared to control and were
decreased twofold or more by NRG-1 were identified and
further analyzed. Principal component analysis (PCA) was
conducted using the Gene Expression Similarity Investiga-
tion Suite software (Genesis; http://genome.tugraz.at/gen-
esisclient/genesisclient_description.shtml). Genesis uses a
three-dimensional coordinate system, where the x-axis
represents the principal component 1 (PC1), the y-axis
PC2, and the z-axis PC3. Data points near to each other
in the PC space are similar in gene expression, whereas
data points that are far apart from each other in the three-
dimensional space are not similar to each other in gene
expression.logy in the cortex and thalamus. Anesthetized rats were pretreated
rior to i.p. injection of DFP (9 mg/kg). NRG-1 or vehicle was administered
received PB, AMN, and water in place of DFP. The CD11b antibody was
, D) and in the lateral dorsal thalamus (B, E, F, G, H) 24 h following DFP
halamus (B) of control animals displayed the characteristic ramified
e same brain regions of DFP-intoxicated animals exhibited morphology
size of the cell body, thickened proximal processes, and decreased
xicated animals treated with NRG-1 (D, F, H) exhibited morphologies that
d FJB (green labeling) showed that in the thalamus, activated microglia were
r activated microglia nor injured neurons were present in the thalamus of
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The DFP-induced genes that were attenuated by NRG-1
were analyzed using Ingenuity Pathway Analysis (Ingenuity®
Systems; http://www.ingenuity.com/products/ipa) and over-
laid onto a global molecular network developed from infor-
mation contained in the Ingenuity Pathways Knowledge
Base. Fischer’s exact test was used to calculate a P value de-
termining the probability that each biological function and/
or canonical pathway or gene network identified is due to
change alone. The canonical pathways that were most sta-
tistically relevant to the dataset were identified. We overlaid
the gene expression profiles on the canonical pathway and
gene network figures to reveal similarities and dissimilar-
ities in their gene expression patterns.
Results and discussion
Neuregulin-1 inhibits DFP-induced microglial activation
DFP is structurally and toxicologically similar to the OP
nerve agents and thus is used as an OP nerve agent stimu-
lant in experimental animal models [29,30]. We previously
demonstrated that rats injected with DFP at 9 mg/kg, i.p.,
experience seizures and exhibited significant delayed neu-
rodegeneration in multiple brain regions [9]. Microglial
activation is a characteristic brain inflammatory response
induced following OP nerve agent intoxication [20,21].
Under normal physiological conditions, resting microglia
display a ramified state; however, when activated, micro-
glia undergo a morphological transformation from theFigure 2 Neuregulin-1 inhibits DFP-induced changes in microglial morpho
were immunostained for CD11b to identify microglia in the hippocampus, and a
immunopositive cells with morphological characteristics of activated microglia (in
administration (A, C). In contrast, CD11b immunopositive cells in the hippocamp
characteristic of resting microglia (B, D). H, hilus; GL, granule cell layer. Stereotaxicresting ramified state to an amoeboid shape. To determine
the effects of acute DFP intoxication on microglia, brain
sections from rats injected with vehicle or DFP in the ab-
sence or presence of NRG-1 were immunostained for
CD11b, a biomarker of microglia [33]. Microglia in the
superficial layers of cortex (Figure 1A) and lateral dorsal
thalamus (Figure 1B) in control animals displayed the
characteristic ramified morphology of resting microglia.
Acute intoxication with DFP caused microglial activation,
as indicated by the increased size of the cell body, a thick-
ening of proximal processes, decreased ramification of
distal branches and/or amoeboid shaped cell bodies of
CD11b immunopositive cells (Figure 1C, E). NRG-1 treat-
ment prevented the DFP-induced morphological changes
of microglial cells in those brain regions (Figure 1D, F) as
CD11b immunopositive cells were morphologically similar
to microglia in control brains. Dual labeling with CD11b
and FJB showed that in the thalamus of animals acutely
intoxicated with DFP, activated microglia were detected in
areas of brain injury (Figure 1G). However, neither acti-
vated microglia nor injured neurons were present in the
thalamus of DFP intoxicated animals treated with NRG-1
(Figure 1H). We previously showed that DFP administra-
tion resulted in neuronal injury in the CA1, CA3, and
dentate gyrus of the hippocampus which was attenuated
by NRG-1 [9]. Similarly, microglial activation was also
seen in the hippocampus, including the dentate gyrus
shown here, following DFP intoxication (Figure 2A, C).logy in the hippocampus. Brains collected 24 h post-DFP administration
subset of these sections was also stained for DAPI (C, D). CD11b
dicated by arrows) were seen in the hippocampus 24 h following DFP
us of DFP intoxicated animals treated with NRG-1 exhibited morphologies
coordinate = bregma −3; Scale bar = 50 μm.
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treatment (Figure 2B, D). NRG-1 treatment did not pre-
vent microglial activation in the amygdala, medial dorsal
thalamus, reunion area of thalamus or piriform cortex of
the DFP intoxicated animal (data not shown), brain re-
gions in which neuronal injury was previously shown to
not be protected by NRG-1 [9].
To confirm the data based on morphological criteria of
resting versus activated microglia, brain sections were also
immunostained using the ED-1 antibody, which is a specific
biomarker of macrophages and activated microglia [33].
There was virtually no ED1 immunoreactivity in the brains
of vehicle control animals, including dorsal lateral thalamus
(Figure 3A). However, there were numerous ED-1 immu-
nopositive macrophages/activated microglia detected in
brain regions of DFP-intoxicated animals. ED-1 immuno-
positive cells were amoeboid shaped (characteristic of
activated macrophages and microglia) and distributed
throughout the dorsal lateral thalamus (Figure 3B) and the
superficial layers of cortex (Figure 3D). However, in DFP-
intoxicated animals pre-treated with NRG-1, only a few
ED-1 immunopositive cells were seen in injured regions ofFigure 3 Neuregulin-1 blocks DFP-induced microglia activation in the
macrophages and activated microglia 24 h following DFP and NRG-1 admi
(red labeling; arrows) in the brain of control animals (A), but there were nu
cortex (D) of DFP treated animals. Treatment with NRG-1 significantly decre
thalamus (C) and cortex (E) of DFP intoxicated animals. Dual labeling for E
seen in areas of the DFP-exposed cortex with significant neurodegeneratio
observed in the cortex of DFP-intoxicated animals that were pretreated witthe dorsal lateral thalamus (Figure 3C) and no ED-1 immu-
nopositive cells were observed in the cortex (Figure 3E).
Dual labeling for ED-1 and FJB showed that activated
microglia were associated with areas of neuronal injury in
the cortex (Figure 3F) of DFP-intoxicated animals. Neither
activated microglia nor injured neurons were observed in
the cortex of DFP-intoxicated animals pre-treated with
NRG-1 (Figure 3G). Similar to observations of CD11b
immunolabeling, there was no change in the density of
ED1 immunopositive cells in the amygdala, reunion area of
thalamus, medial dorsal thalamus, and piriform cortex (data
not shown), which were previously shown to be non-
responsive to the neuroprotective effects of NRG-1 [9].
DFP induced ED-1 immunoreactivity in the hippocampus
(Figure 4A), which was significantly reduced by NRG-1
pre-treatment (Figure 4B). Labeling of adjacent hippocam-
pal sections of the dentate gyrus with ED-1 and FJB
indicated that ED-1 immunoreactivity was detected both
within and outside the hilar region where there were signifi-
cant numbers of FJB stained neurons (Figure 4C) but in the
hippocampi of DFP-intoxicated rats treated with NRG-1,
there was no FJB labeling (Figure 4D).cortex and thalamus. The ED-1 antibody was used to identify
nistration. There was virtually no ED1 immunoreactivity detected
merous ED1 immunopositive cells detected in the thalamus (B) and
ased the number of ED1 immunopositive cells detected in the
D-1 and FJB (green labeling) showed that activated microglia were
n (F) and that neither activated microglia nor injured neurons were
h NRG-1 (G). Scale bar = 50 μm.
Figure 4 Neuregulin-1 blocks DFP-induced microglia activation in the hippocampus. Labeling of adjacent sections from the dentate gyrus
of the hippocampus showed that in DFP intoxicated animals, ED-1 immunoreactivity (A; arrows) coincided with regions of FJB stained neurons
(C). In contrast, in DFP intoxicated animals pretreated with NRG-1, virtually no ED-1 immunoreactivity (B) or FJB staining (D) was observed. H,
hilus; GL, granule cell layer. Stereotaxic coordinate = bregma −3; Scale bar = 50 μm.
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To examine gene expression profiles, total RNA was iso-
lated from the hippocampus of each experimental group
(control, DFP, and DFP +NRG-1) at 24 h post-DFP injec-
tion and interrogated using the rat genome U230 2.0 Gene-
Chip that contains approximately 30,000 probe sets
(transcripts). To assess inter-experiment differences in the
intensity of gene expression, replicated experiments were
compared for each experimental group and analyzed by
principle component analysis (PCA). Similarity between
data points in the PCA was determined by the distance
between the points in the three-dimensional plot gener-
ated, with shorter distance indicating increased similarity
(Figure 5A). Each data point represents one animal’s gene
expression profile. Control, DFP, and DFP +NRG-1 gene
expression profiles clustered within treatment groups, but
the control group was well isolated from the other two
treatment groups and the profiles for DFP and DFP +
NRG-1 treatment groups were similar. To examine the
changes in gene expression, we compared the gene ex-
pression profiles of the vehicle controls to the DFP ani-
mals and the gene expression profiles of the DFP animals
to the DFP +NRG-1 animals. Figure 5B is a heat map il-
lustrating that many genes were induced following DFP
administration and that a very small subset of those genes
were attenuated by NRG-1 treatment.
The set of genes induced by two-fold or more at 24 h
following DFP administration (1,298 transcripts) and thatwere suppressed 50% or more by treatment with NRG-1
(41 transcripts) was imported into the IPA software to
examine functions and pathways associated with this sub-
set of genes. Analysis of the top ten canonical pathways
associated with the dataset in IPA shows that most of
these pathways are associated with immune function
(Figure 6). Immune cell trafficking (agranulocytes and
granulocyte adhesion and diapedesis), cytokine (IL-17
and IL-6) signaling, and acute phase response signaling
were ranked among the most significant pathways, con-
sistent with a key role for inflammation in mediating the
delayed neural injury associated with OP neurotoxicity.
The full list of genes that passed the fold change and false
discovery rate cutoffs, including names and the GenBank
accession numbers, is provided in Table 1. The DFP-
induced genes that were significantly attenuated by NRG-1
treatment included the cytokine IL-1β, chemokines CXCL2
and CXCL11, and leukocyte cell derived chemotaxin-1
(LECT1). DFP increased the expression of paraoxonase-1
(PON1), an enzyme involved in the hydrolysis of organo-
phosphates and NRG-1 suppressed the induction of PON-1
by DFP.
NRG-1 reduces DFP-induced mRNA levels of pro-
inflammatory cytokines in the brain
To confirm the microarray results indicating an effect of
NRG-1 on pro-inflammatory cytokine mRNA expression,
we used real-time RT-PCR to determine the levels of IL-
1β, IL-6, and TNFα in hippocampal tissues 24 h following
A B
Figure 5 NRG-1 prevents DFP-induced hippocampal gene expression. Gene expression profiles in the hippocampus of three treatment groups
(control, DFP, and DFP + NRG-1) were determined by mRNA microarray using the rat genome U230 2.0 GeneChip that contains approximately 30,000
probe sets (transcripts). (A) To assess inter-experiment differences in the intensity of gene expression, replicate experiments were compared for each
experimental group and the resulting datasets analyzed by principle component analysis (PCA). The control samples clustered together and were
distinct from and not overlapping with the DFP and DFP + NRG-1 groups, which were similar to each other. (B) Hierarchical cluster analysis graphically
illustrates that approximately 1,300 genes were induced following DFP administration and that the induction of a small subset of these (indicated by
the arrow) were attenuated by NRG-1 pretreatment. Green indicates genes with low level or no expression and red indicates genes with increased
expression levels. Three animals were compared from each treatment group: (1) control; (2) DFP; and (3) DFP + NRG-1. DFP, diisopropylflurophosphate;
NRG-1, neuregulin-1.
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showed that IL-1β and IL-6, but not TNFα, were upregu-
lated by DFP. Pretreatment with NRG-1 reduced levels of
DFP-induced IL-1β mRNA by more than 50% of the levels
observed in DFP intoxicated animals. DFP-induced levelsof IL-6 mRNA were also reduced by NRG-1 but by less
than the 50% cutoff, and NRG-1 treatment did not affect
levels of DFP-induced TNFα mRNA. Similarly, real-time
RT-PCR results showed that IL-1β and IL-6 were strongly
induced by DFP in the brain while relatively little was seen
Figure 6 Pathway analyses of gene differentially regulated by NRG-1 pretreatment of DFP intoxicated animals. DFP-induced genes that
were suppressed 50% or more by pretreatment with NRG-1 were analyzed using Ingenuity Pathway Analysis (IPA) software to identify canonical
pathways associated with this subset of genes. IL, interleukin.
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microarray results, DFP-induced IL-1β and IL-6 mRNA
levels were reduced by NRG-1. TNFα levels were un-
changed by either DFP or NRG-1 at 24 h post-DFP injec-
tion (Figure 7C).
Although there has been progress with efforts to treat
patients with acute symptoms following OP exposure,
strategies to prevent the subsequent OP-induced delayed
neuronal injury are currently unavailable. It is well estab-
lished that OP intoxication results in the stimulation of
pro-inflammatory responses that lead to neuronal injury
and increased neurological impairment [2,15-19]. OPs ini-
tiate inflammatory responses in the injured brain that pro-
gress for days after the onset of symptoms. Experimental
studies show that inflammatory reactions in the brain can
enhance neuronal excitability and impair cell survival, and
conversely, some anti-inflammatory treatments reduce
brain pathology in animal models of acute CNS injury
[2,34]. Therefore, interventions that are aimed at decreas-
ing neuroinflammation have potential as therapeutic
agents for treating humans poisoned with OP neurotoxins
and nerve agents.
Recent studies from our lab showed that NRG-1 treat-
ment significantly reduced DFP-induced delayed neuronal
damage and oxidative stress in rats when administered up
to 1 h following DFP intoxication [9,30]. One of the early
consequences of OP intoxication is the activation of brain
microglia [2,20,21,35], therefore, in this study, we examined
whether NRG-1 could regulate DFP-induced microglial ac-
tivation in the brain. Our data demonstrated that NRG-1
blocked DFP-induced morphological changes in microglia
associated with activation and subsequent delayed neuronal
damage. The region specific anti-inflammatory effects ofNRG-1 are consistent with our findings showing selective
DFP-induced neuronal injury and neuroprotection by
NRG-1 [9,30]. We proposed that the effects could be the
result to several factors, including access of exogenously
administered NRG-1 to various brain regions, selective vul-
nerability of specific neurons and/or and regional differ-
ences in NRG-1 receptor expression.
To elucidate the molecular mechanisms used by NRG-
1 to block microglia activation and neuronal injury, we
examined gene expression profiles in hippocampal brain
tissues following DFP intoxication and NRG-1 treat-
ment. DFP increased the expression of nearly 1,300 tran-
scripts by twofold or more, however only 41 of those
genes were suppressed 50% or more by NRG-1. Bioinfor-
matic analysis of the NRG-1 suppressed genes with IPA
software indicated that immune cell trafficking, hepatic
fibrosis/hepatic stellate cell activation, acute phase re-
sponse, and IL-6 signaling were among the top canonical
pathways associated with the anti-inflammatory and
neuroprotective effects of NRG-1. These findings are
similar to studies that analyzed gene expression profiles
of the prefrontal cortex from rats 24 h after soman ex-
posure [36].
Activated brain microglia release pro-inflammatory cyto-
kines following OP poisoning, which are toxic to neurons
[2,22-27]. Inflammatory cytokines, such as IL-1α, IL-1β, IL-
6, and TNFα are induced in the rodent brain following OP
intoxication [22-27]. IL-1β is primarily expressed by acti-
vated brain microglia following OP exposure [25]. NRG-1
attenuated the induction of IL-1β in addition to the chemo-
kines CXCL2, CXCL11, and LECT1. Interestingly, NRG-1
attenuated the DFP-induced upregulation of paraoxonase-
1 (PON1), an enzyme involved in the hydrolysis of
Table 1 Genes induced 2-fold by DFP and suppressed 50% or more by NRG-1




1367794_at A2m Alpha-2-macrolobulin 2.34 −2
1369625_at Aqp1 Aquaporin 1 5.1 −17.93
1383946_at Cldn 1 Claudin 1 3.94 −5.7
1375933_at Cldn 2 Claudin 2 2.44 −25.97
1393891_at Col8a 1 Collagen, type VIII, alpha 1 2.73 −5.42
1374172_at Col8a 2 Collagen, type VIII, alpha 2 3.37 −19.49
1370391_at Crabp 2 Cellular retinoic acid binding protien 2 2.18 −2.04
1379365_at Cxcl 11 Chemokine (C-X-C motif) ligand 11 17.41 −2.13
1368760_at Cxcl 2 Chemokine (C-X-C motif) ligand 2 2.67 −2.61
1367700_at Fmod Fibromudolin 2.02 −8.91
1387889_at Folr 1 Folate receptor 1 (adult) 3.9 −12.25
1368337_at Glycam Glycosylation-dependent cell adhesion molecule 1 3.81 −7.01
1393840_at Gnat 2 Guanine nucleotide protein (G protein), alpha transducing activity polypeptide 2 2.68 −2.52
1391915_at Hspa 9 Heat shock protein 9 2.02 −2.13
1398256_at II 1b Interleukin 1 beta 3.08 −2.13
1387050_s_at Kng 1 Kininogen 1; kininogen 1-like 1; kininogen 2 3.46 −3.31
1387868_at Lbp Lipopolysaccharide binding protien 3.31 −2.62
1387164_at Lect 1 Leukocyte cell derived chemotaxin 1 4.8 −5.56
1393210_at LOC100361383 Extracellular matrix protein 2-like 2.11 −2.09
1375465_at Otx 2 Homeobox protein OTX2-like; orthodenticle homeobox 2 2.51 −17.47
1375908_at Mpzl 2 Myelin protein zero-like 2 4.06 −4.16
1368302_at Msx1 Msh homeobox 1 2.04 −5.63
1371849_at Nt5dc2 5′-nucleotidase domain 2 2.13 −4.9
1385248_a_at Ogn Osteoglycin 2.38 −2.16
1375367_at Pdlim PDZ and LIM domain 2 2.67 −3.73
1370068_at Pla2g5 Phospholipase A2, group V 3.01 −7.5
1371050_at Pon1 Paraoxonase 1 2.48 −3.99
1370012_at Ptgis Prosta landin l2 (prostacyclin) synthase 2.75 −2.74
1380334_at Rbm47 RNA binding motif protein 47 2.11 −3.46
1385500_at RGD1561795 Similar to RIKEN cDNA 1700012B09 2.96 −5.52
1387125_at S100a9 S100 calcium binding protein A9 6.6 −2.88
1377034_at Serpin1a Serine (or cysteine) proteinase inhibitor, clade B, member 1a 3.07 −2.2
1385005_at Slc22a8 Solute carrier family 22 (organic anion transporter), member 8 2.12 −3.45
1368606_at Slco1a5 Solute carrier organic transporter family, member 1a5 4.34 −48.37
1367998_at Slpi Secretory leukocyte peptidaase inhibitor 5.12 −2.32
1390525_a_at Stra6 Stimulated by retinoic acid gene 6 2.64 −4.31
1384522_at Sytl3 Synaptotagmin-like 3 2 −2.06
1383606_at Tc2n Tandem C2 domains, nuclear 4.01 −3.59
1387013_at Tmem27 Transmembrane protein 27 4.53 −34.51
1388557_at Tubb4b Tubulin, beta 4B class IVb 2.24 −4.21
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known to be mediated by inflammatory responses [37].
NRG-1 increased brain protein levels of IL-10, an anti-inflammatory cytokine that represses the expression of IL-
1, IL-6, and TNFα by activated macrophages [38]. Consist-
ent with this finding, we recently showed that NRG-1
Figure 7 NRG-1 reduces DFP-induced expression of pro-inflammatory cytokine mRNA in the brain. RNA was isolated from the hippocampus
and analyzed by RT-PCR to quantify the expression of mRNA for IL-1β (A), IL-6 (B), and TNFα (C) (n = 7 to 9 biological replicates for each condition).
The data are presented as mean ± SEM of the relative mRNA (in arbitrary values) levels in naive, control, DFP, and DFP + NRG-1-treated rats after
normalization to GAPDH mRNA levels (**P < 0.01; ***P < 0.001; ****P < 0.0001).
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inflammatory cytokines, and increased survival in a
mouse model of cerebral malaria [39]. NRG-1 sup-
pressed the levels of TNFα, IL-6, IL-1α, and CXCL10,
while inducing the anti-inflammatory cytokines IL-5
and IL-13. NRG-1 was effective despite having no effect
on parasite load during the treatment, suggesting that
NRG-1 can alter the immune state to prevent cellular
damage following acute CNS injuries.
NRG-1 has previously been shown to affect microglial
and macrophage activation [40-46]. NRG-1 reduced free
radical release from cultured mouse microglial cells [40],
and studies from our laboratory showed that NRG-1 sup-
pressed cyclooxygenase-2 (COX-2) expression in activated
human monocyte/macrophage cell cultures [41]. NRG-1
also stimulated microglial proliferation and chemotaxis in
a rat model of peripheral nerve injury (PNI) [42,43].
Microglial activation and NRG-1 receptor activation fol-
lowing PNI peaked around 3 days after injury suggesting
that microglial activation by NRG-1 may be associated
with neuronal repair rather than acute neurotoxicity. The
neuropathological and neuroinflammatory sequelae of
acute OP poisoning are similar to those observed in other
acute CNS injuries, such as stroke, brain trauma, and sta-
tus epilepticus [15-19,47,48]. Studies from our laboratory
and others demonstrated that administration of NRG-1reduced delayed ischemic brain damage and improved
functional recovery in a rat middle cerebral artery occlu-
sion (MCAO) stroke model [32,49-52]. NRG-1 prevented
macrophage/microglial activation, reactive astrogliosis,
neuronal apoptosis, and pro-inflammatory cytokine ex-
pression following stroke [41,50,52]. Taken together, these
studies suggest that the neuroprotective efficacy of NRG-1
in DFP-induced brain injury, ischemic stroke, and cerebral
malaria might be explained, at least in part, by regulating
the immune response and inflammatory mediators.
Recent clinical studies have demonstrated the utility of
NRG-1 in human patients with congestive heart failure
[53,54]. Phase I clinical studies in China (Chinese Clinical
Trial: ChiCTR-TRC-00000414) and Australia (Australian
New Zealand Clinical Trials Registry: ACTRN126070003
30448) showed that NRG-1 was safe in both healthy and
heart failure patients. Recombinant human NRG-1 was used
in phase II clinical trials investigating its efficacy in patients
with chronic heart failure in both the Australian and
Chinese studies [53,54]. In these studies, patients received
placebo or NRG-1 at a dose of 0.3 to 1.2 μg/kg/day intra-
venously for 10 days, in addition to standard drug therap-
ies. During a follow-up period 11 to 90 days after study
initiation, NRG-1 significantly improved heart function in
patients and the effective doses were shown to be safe and
tolerable. Three additional clinical trials to determine the
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ure have been initiated in the US (ClinicalTrails.gov identi-
fiers NCT01258387; NCT01944683; NCT01251406). The
doses of NRG-1 that showed efficacy for treating heart fail-
ure are near the doses used in our rat stroke and OP studies.
In these studies, we showed that NRG-1 was neuroprotec-
tive after a single i.a. administration of NRG-1. However, we
expect that i.v. administration of NRG-1 will similarly pro-
vide neuroprotection as previously demonstrated in other
models of acute brain injury [51,55].
In conclusion, our data demonstrate that treatment with
NRG-1 blocks the activation of microglia by DFP and de-
creases DFP-induced pro-inflammatory expression in
brain tissues. Our results suggest that NRG-1 protects
neurons against DFP-induced delayed cell death by inhi-
biting toxic pro-inflammatory responses. These findings
indicate that NRG-1 has enormous clinical potential and
could lead to the development of effective medical coun-
termeasures to facilitate better emergency treatment and
protection of civilians and military personnel following ex-
posure to OP nerve agents.
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